Evaluation of toxicities from combined metronomic and maximal-tolerated dose chemotherapy in dogs with osteosarcoma.

OBJECTIVE To evaluate the tolerability of a piroxicam and cyclophosphamide metronomic treatment protocol combined with carboplatin alone or carboplatin and doxorubicin at maximal-tolerated doses. METHODS Retrospective study of 30 dogs diagnosed with osteosarcoma. All dogs underwent amputation and chemotherapy treatment with one of the two maximal-tolerated dose protocols. Metronomic chemotherapy was administered in conjunction with these protocols, and continued subsequently. The protocols included 0 · 3 mg/kg piroxicam and 10 to 12 mg/M(2) cyclophosphamide with 300 mg/M(2) carboplatin alone, or 300 mg/M(2) carboplatin alternating with 30 mg/M(2) doxorubicin. RESULTS Fourteen dogs were treated with the carboplatin and metronomic protocol and 16 were treated with the carboplatin alternating with doxorubicin and metronomic protocol. Grades 3 and 4 toxicities overall were significantly (P = 0 · 018) more common in the former group. The disease-free interval of the carboplatin and metronomic group was 192 days, which was not significantly different (P = 0 · 916) to the 182 days for the carboplatin alternating with doxorubicin and metronomic group. The median survival times of the two groups were 217 and 189 days, respectively. CLINICAL SIGNIFICANCE Piroxicam and cyclophosphamide metronomic protocols can be safely administered in combination with maximal-tolerated dose chemotherapy protocols. A significantly higher frequency of toxicities was observed in dogs treated with the carboplatin and metronomic protocol.

[1]  D. Thamm,et al.  Preliminary evidence for biologic activity of toceranib phosphate (Palladia(®)) in solid tumours. , 2012, Veterinary and comparative oncology.

[2]  D. Vail,et al.  Safety evaluation of combination toceranib phosphate (Palladia®) and piroxicam in tumour-bearing dogs (excluding mast cell tumours): a phase I dose-finding study. , 2012, Veterinary and comparative oncology.

[3]  D. Knapp,et al.  Prospective trial of metronomic chlorambucil chemotherapy in dogs with naturally occurring cancer. , 2012, Veterinary and comparative oncology.

[4]  D. Thamm,et al.  Clinical and immunomodulatory effects of toceranib combined with low-dose cyclophosphamide in dogs with cancer. , 2012, Journal of veterinary internal medicine.

[5]  D. Thamm,et al.  Low-dose cyclophosphamide selectively decreases regulatory T cells and inhibits angiogenesis in dogs with soft tissue sarcoma. , 2011, Journal of veterinary internal medicine.

[6]  J. Schellens,et al.  Determination of platinum originating from carboplatin in human urine and canine excretion products by inductively coupled plasma mass spectrometry. , 2011, Journal of analytical toxicology.

[7]  J. Bryan,et al.  Tolerability of metronomic administration of lomustine in dogs with cancer. , 2011, Journal of veterinary internal medicine.

[8]  Scott A. Brown,et al.  Evaluation of the Renal Effects of Ibuprofen and Carprofen in Euvolemic and Volume-depleted Dogs , 2011 .

[9]  H. Hoogsteden,et al.  Low-Dose Cyclophosphamide Synergizes with Dendritic Cell-Based Immunotherapy in Antitumor Activity , 2010, Journal of biomedicine & biotechnology.

[10]  B. Powers,et al.  Use of single-agent carboplatin as adjuvant or neoadjuvant therapy in conjunction with amputation for appendicular osteosarcoma in dogs. , 2009, Journal of the American Animal Hospital Association.

[11]  S. Dow,et al.  Metronomic therapy with cyclophosphamide and piroxicam effectively delays tumor recurrence in dogs with incompletely resected soft tissue sarcomas. , 2008, Journal of veterinary internal medicine.

[12]  Hyunsook Kim,et al.  Cyclooxygenase-2 promotes cell proliferation, migration and invasion in U2OS human osteosarcoma cells , 2007, Experimental & Molecular Medicine.

[13]  G. Ogilvie,et al.  Doxorubicin and BAY 12-9566 for the treatment of osteosarcoma in dogs: a randomized, double-blind, placebo-controlled study. , 2007, Journal of veterinary internal medicine.

[14]  S. Dow,et al.  Continuous low-dose oral chemotherapy for adjuvant therapy of splenic hemangiosarcoma in dogs. , 2007, Journal of veterinary internal medicine.

[15]  D. Argyle,et al.  The in vitro effects of piroxicam and meloxicam on canine cell lines. , 2006, The Journal of small animal practice.

[16]  Annette N Smith,et al.  Toxicity and efficacy of cisplatin and doxorubicin combination chemotherapy for the treatment of canine osteosarcoma. , 2005, Journal of the American Animal Hospital Association.

[17]  R. Kerbel,et al.  Low-dose metronomic combined with intermittent bolus-dose cyclophosphamide is an effective long-term chemotherapy treatment strategy. , 2005, Cancer research.

[18]  P. Snyder,et al.  Carboplatin and piroxicam therapy in 31 dogs with transitional cell carcinoma of the urinary bladder. , 2005, Veterinary and comparative oncology.

[19]  G. Ogilvie,et al.  Cyclooxygenase-2 expression in canine appendicular osteosarcomas. , 2004, Journal of veterinary internal medicine.

[20]  B. Séguin,et al.  Alternating Carboplatin and Doxorubicin as Adjunctive Chemotherapy to Amputation or Limb-Sparing Surgery in the Treatment of Appendicular Osteosarcoma in Dogs , 2004 .

[21]  R. Kerbel,et al.  Maximum tolerable dose and low-dose metronomic chemotherapy have opposite effects on the mobilization and viability of circulating endothelial progenitor cells. , 2003, Cancer research.

[22]  N. Shenoy,et al.  Phase I dose-escalating study of SU11654, a small molecule receptor tyrosine kinase inhibitor, in dogs with spontaneous malignancies. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[23]  D. Argyle,et al.  A landmark in Veterinary and Comparative Oncology. , 2003, Veterinary and comparative oncology.

[24]  H. Erb,et al.  Carboplatin and doxorubicin combination chemotherapy for the treatment of appendicular osteosarcoma in the dog. , 2003, Journal of veterinary internal medicine.

[25]  Peter Bohlen,et al.  Antitumor effects in mice of low-dose (metronomic) cyclophosphamide administered continuously through the drinking water. , 2002, Cancer research.

[26]  Gabriele Bergers,et al.  Less is more, regularly: metronomic dosing of cytotoxic drugs can target tumor angiogenesis in mice. , 2000, The Journal of clinical investigation.

[27]  Y. Sasaki,et al.  Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. , 1999, Laboratory investigation; a journal of technical methods and pathology.

[28]  D. Knapp,et al.  Amputation and carboplatin for treatment of dogs with osteosarcoma: 48 cases (1991 to 1993). , 1996, Journal of veterinary internal medicine.

[29]  W. Rand,et al.  Prognosis for dogs with appendicular osteosarcoma treated by amputation alone: 162 cases (1978-1988). , 1992, Journal of the American Veterinary Medical Association.

[30]  H. Dorfman,et al.  Primary and secondary bone tumours in the cat. , 1974, The Journal of small animal practice.